pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
552
stories
Sep 4, 26
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
biopharma dive
Sep 4, 26
US-China biotech NeuShen gets $80M to develop brain-health drugs
endpoints
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 4, 26
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
biospace
Sep 3, 26
GSK wagers up to $1.3B on a different kind of cancer drug
biopharma dive
Sep 3, 26
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
fiercebiotech
Sep 3, 26
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
endpoints
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
Sep 3, 26
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
Sep 3, 26
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
biospace
Sep 3, 26
Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal
fiercebiotech
Sep 3, 26
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
biospace
Sep 3, 26
Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
endpoints
Sep 3, 26
GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront
endpoints
Sep 3, 26
AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial
fiercebiotech
Sep 3, 26
GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset
fiercebiotech
Sep 2, 26
Teva says gluten challenge study succeeds in celiac disease
endpoints
Sep 2, 26
Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
biopharma dive
Sep 2, 26
STAT+: ARPA-H funds biotechs working on custom RNA therapies
stat
Sep 2, 26
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
biospace
Sep 2, 26
Teva autoimmune antibody notches ph. 2 win in celiac disease
fiercebiotech
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Sep 1, 26
From his parents’ basement to your medicine cabinet: Absci CEO endeavors to create biotech’s Apple
fiercebiotech
Sep 1, 26
Roche finds another oncology gem in Asia with $1.5B B cell disease partnership
biospace
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Aug 31, 26
Deal-hungry Lilly strikes up to $2.9B immuno play for Merida
biospace
Aug 31, 26
A winner, a loser, and a mid-stage signal from a major cardiology research conference
stat
Aug 31, 26
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
Aug 31, 26
Natera teams with Angiex on cancer drug trial monitoring
fiercebiotech
Aug 31, 26
BMS’ neuro renaissance was built on back of Celgene mega-merger
biospace
← prev
page 6 of 19
next →
